Targeted α-Particle Radiotherapy for Cancer

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary diagnostics that utilize the same targeting peptide which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.

Viewpoint is teaming with world-class companies and academic centers to bring its novel product line of therapeutics and complementary diagnostic imaging agents to personalized patient care for metastatic melanoma and neuroendocrine tumors.

Viewpoint Molecular Targeting™ Chief Scientific Officer, Dr. Michael Schultz, Discusses the Promise of Image-Guided 212Pb Alpha-Particle Radiopharmaceutical Therapies for Cancer at the SNMMI 2021 Annual Meeting

Coralville, IA, June 15, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced that Michael K. Schultz PhD, Chief Science Officer of Viewpoint presented at The Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held virtually June 11-15, 2021.
READ MORE

Viewpoint Molecular Targeting™ Commences Patient Enrollment in Phase 1 Imaging Study for VMT01 Program for Metastatic Melanoma

Coralville, IA, June 10, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced it has initiated patient enrollment and screening in its Phase 1 imaging study evaluating VMT01 for the treatment of metastatic melanoma.
READ MORE
 

Viewpoint Molecular Targeting™ Bolsters its Board of Directors with Appointment of Charles Link, M.D., FACP

Coralville, IA, May 18, 2021 – Viewpoint Molecular Targeting, Inc. (“Viewpoint” or the “Company”), a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Charles Link, M.D., FACP
to its Board of Directors.

READ MORE